• K Prasad, J Volmink, and G R Menon.
• Arabian Gulf University, College of Medicine & Medical Sciences, PO Box 22979, Manama, Bahrain. prasadk@agu.edu.bh
• Cochrane Db Syst Rev. 2007 Jul 18 (1): CD002244.

BackgroundEven though corticosteroids have been used alongside antituberculosis drugs for tuberculous meningitis (TBM) since the 1950s their role remains controversial. Some believe corticosteroids improve outcome while others point to the lack of supportive evidence. In patients who are immunocompromised because of HIV infection the risks and benefits of steroids are unknown.ObjectivesTo assess the effects of steroids on death and disability in patients with TBM.Search StrategyWe searched the Cochrane Infectious Diseases Group specialized trials register (February 2005), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2005), MEDLINE (1966 to February 2005), EMBASE (1980 to February 2005), and LILACS (February 2005).Selection CriteriaRandomised controlled trials of steroids in people on TB treatment for TBM.Data Collection And AnalysisTwo independent reviewers applied study selection criteria, assessed methodological quality and extracted data.Main ResultsSix trials of 595 patients met the inclusion criteria. No study described allocation concealment. Steroids were associated with fewer deaths (relative risk [RR] 0.79; 95% confidence interval [CI] 0.65 to 0.97) and a reduced incidence of death and severe residual disability (RR 0.58, 95% CI 0.38 to 0.88). Subgroup analysis suggests an effect on mortality in children (RR 0.77, 95% CI 0.62 to 0.96) but the results in a smaller number of adults are inconclusive (RR 0.96, 95% CI 0.50 to 1.84). There is little evidence that the severity of disease influences the effects of steroids on mortality.Authors' ConclusionsAdjunctive steroids might be of benefit in patients with TBM. However, existing studies are small, and poor allocation concealment and publication bias may account for the positive results found in this review. No data are available on the use of steroids in HIV positive persons. Future placebo-controlled studies should include patients with HIV infection and should be large enough to assess both mortality and disability.

22 keywords...

hide…